Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions - Full Text View

Sponsored by:	M.D. Anderson Cancer Center
Information provided by:	M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:	NCT00527891

Purpose

Primary Objective:

1. To compare the efficacy of 1.5T vs. 3T T1 and T2-weighted MR images sequences for the detection and evaluation of liver lesions.

Condition	Intervention	Phase
Liver Cancer	Procedure: Signa Excite 3.0 T MRI Scan	Phase I

MedlinePlus related topics: Cancer Liver Cancer MRI Scans Nuclear Scans

U.S. FDA Resources

Study Type:	Observational
Study Design:	Natural History, Longitudinal, Defined Population, Prospective Study
Official Title:	Evaluation of the Signa Excite 3.0 T MRI Excite for Detection and Characterization of Liver Lesions

Further study details as provided by M.D. Anderson Cancer Center:

Estimated Enrollment:	20
Study Start Date:	June 2004

Detailed Description:

Magnetic resonance imaging is taken with scanners at different magnetic field strength. The current practice at UTMDACC is to perform these exams at 1.5 Tesla. Tesla is the unit of strength of the magnetic field. This study will compare the images taken at the standard 1.5 Tesla (T) magnetic field with those at the newer 3.0T magnetic field.

You are already scheduled to receive a standard 1.5 T MR of the liver area as requested by your doctor. As part of this study, you will then be asked to return on a separate date to have a similar exam performed with the Signal 3.0T Excite MR scanner. You will return within a two week period from the date of your first MRI examination. The examination will be performed in a machine that looks similar to the 1.5T scanner. It will also take about the same amount of time as the examination at 1.5T.

The images taken by both scanners will be evaluated and compared. After you have had the second scan, your participation in this study will be over. If there are new findings identified with the new scan your doctor will be notified.

This is an investigational study. The 3.0T scan will be performed free of charge. A total of 20 patients will take part in this study All will be enrolled at UTMDACC.

This protocol is partially funded by a research grant from General Electric Medical Systems (GEMS).

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Patients with a liver lesion larger than 1cm detected by a prior imaging modality.
Patients have been scheduled and are eligible for an MRI of the abdomen or MRI of the liver or MRI of the kidney examination.

Exclusion Criteria:

1) Patients who are unable to cooperate with breath hold.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00527891

Locations

United States, Texas
U.T.M.D. Anderson Cancer Center
Houston, Texas, United States, 77030

Sponsors and Collaborators

M.D. Anderson Cancer Center

Investigators

Principal Investigator:

Janio Szklaruk, MD

U.T.M.D. Anderson Cancer Center

More Information

Study ID Numbers:	2003-1051
Study First Received:	September 10, 2007
Last Updated:	September 26, 2007
ClinicalTrials.gov Identifier:	NCT00527891
Health Authority:	United States: Institutional Review Board

Keywords provided by M.D. Anderson Cancer Center:

Liver Cancer
Magnetic Resonance Imaging
Signa Excite 3.0T MRI Scan

Study placed in the following topic categories:

Liver Neoplasms
Liver Diseases
Digestive System Diseases

Digestive System Neoplasms
Liver neoplasms
Gastrointestinal Neoplasms

Additional relevant MeSH terms:

Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 14, 2009